Company profile
Praxis Precision Medicines, Inc.
PRAX · NASDAQ (CNS precision-neuroscience biopharma, actively listed and trading (NASDAQ: PRAX; ~$8.8B market cap as of Jul 2026, Q2-2026 earnings call scheduled for Aug 6 2026 at time of research) — verified currently listed, no rename/delisting/solvency issue found. Not present in the roster. Sources: https://clinicaltrials.gov/study/NCT05737784 ; https://data.sec.gov/submissions/CIK0001689548.json ; https://www.stocktitan.net/overview/PRAX/ ; https://www.nasdaq.com/market-activity/stocks/prax Entity resolved by asset-pipeline-v2.)
Share price · PRAX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | SCN2A (antisense knockdown)RNA / oligonucleotide | Epilepsy | |
| Phase 3 | Voltage-gated sodium channelSmall molecule | Epilepsy | |
| Phase 3 | Voltage-gated sodium channel · Voltage-gated sodium channel (persistent current)Small molecule | Epilepsy | |
| Phase 3 | Voltage-gated sodium channelSmall molecule | Epilepsy | |
| Phase 2 | SCN2A mRNARNA / oligonucleotide | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.